Philips stock declines amid sleep apnea market growth forecast
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy PHG?
Source: Yahoo Finance
Philips shares fell 5.24% as the stock crossed below the 5-day SMA, reflecting investor concerns despite positive market forecasts for sleep apnea devices.
The global sleep apnea devices market is projected to grow significantly, expanding from USD 7.95 billion in 2025 to USD 14.68 billion by 2034, driven by increased awareness and technological advancements. However, Philips' stock decline suggests sector rotation, as investors may be reallocating funds to other opportunities despite the promising market outlook.
This decline may indicate a temporary setback for Philips, as the overall market for sleep apnea devices shows strong growth potential, which could benefit the company in the long run.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHG
About PHG
Koninklijke Philips NV is a Netherlands-based health technology company. The Company's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care businesses and Other. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease as well as oral healthcare and mother and child care support. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The Other segment comprises such items, as innovation, emerging businesses, royalties, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Global Sleep Apnea Devices Market Growth Forecast
- Market Size Growth: The global sleep apnea devices market is projected to expand from USD 7.95 billion in 2025 to USD 14.68 billion by 2034, growing at a CAGR of 7.05%, reflecting increased awareness of sleep disorders and technological advancements.
- Expanding Patient Base: Approximately 1 billion individuals globally are affected by sleep apnea, with 936 million suffering from obstructive sleep apnea, and over 30 million in the U.S., indicating significant market demand potential.
- Technological Innovation Drive: Recent advancements have made sleep apnea devices smaller, quieter, and more portable, while the introduction of smart devices enhances treatment effectiveness and patient comfort, propelling market growth.
- Homecare Trend: The increasing preference for home-based healthcare solutions has significantly boosted demand for sleep apnea devices, particularly as insurance coverage expands, making home testing devices like NightOwl more appealing.
See More
Philips Rembra Platform Receives FDA Clearance
- FDA Clearance: Philips' Rembra CT, Rembra RT, and Areta RT systems have received 510(k) clearance from the U.S. FDA, marking a significant advancement in high-throughput imaging and cancer treatment planning, expected to enhance efficiency and quality in healthcare services.
- High-Throughput Imaging Capability: The Rembra CT system supports up to 270 exams per day, designed for emergency, critical care, and interventional settings, enabling clinicians to make timely decisions in critical moments, thus improving the coherence of patient care.
- Precision Treatment Planning: Rembra RT and Areta RT systems feature an 85 cm extended field of view and next-generation 4DCT imaging capabilities, allowing for more accurate tumor targeting while protecting healthy tissue, thereby enhancing the personalization and precision of cancer treatment and reducing variability in the treatment process.
- Integrated Healthcare Workflows: The Rembra platform aims to enhance the efficiency and confidence of healthcare providers by integrating diagnostic and therapeutic solutions, further solidifying Philips' market position in the CT field to meet the growing demand for imaging.
See More
Philips Receives FDA Clearance for First AI-Powered Spectral CT
- FDA Clearance: Philips' Spectral CT Verida system has received FDA 510(k) clearance, becoming the world's first AI-powered spectral CT scanner for clinical use, marking a significant advancement in medical imaging technology.
- Enhanced Imaging Efficiency: The system can reconstruct up to 145 images per second, reducing full-body exam times to under 30 seconds and supporting up to 270 exams per day, significantly improving workflow efficiency in high-volume departments.
- Broad Clinical Applications: The Verida system is cleared for head, whole-body, cardiac, and vascular CT imaging, and is also indicated for oncology treatment planning, providing simultaneous conventional and spectral results to enhance tissue characterization capabilities.
- Personalized Adjustments: The updated computing infrastructure allows clinicians to adjust image de-noising levels based on personal preferences, ensuring customization without compromising spectral output, further enhancing the accuracy of clinical decision-making.
See More
Philips Launches AI-Powered Spectral CT System
- FDA Clearance: Philips' Spectral CT Verida system has received FDA 510(k) clearance, marking the entry of its AI-powered spectral CT innovation into the U.S. market, which is expected to enhance imaging quality and clinical decision-making efficiency.
- Image Reconstruction Capability: The Verida system reconstructs 145 images per second, allowing entire exams to be completed in under 30 seconds, which is twice as fast as before, significantly improving workflow efficiency to meet high patient throughput demands in radiology.
- Broad Clinical Applications: This system is applicable across radiology, interventional radiology, and cardiology, capturing both high- and low-energy data simultaneously, which supports enhanced tissue characterization and material differentiation, thereby improving clinical insights from imaging.
- Market Strategy Expansion: By combining spectral imaging with AI reconstruction, Verida not only enhances image quality but also expands the role of CT across clinical pathways, bolstering Philips' competitive position in the healthcare technology sector.
See More
Charter Launches Spectrum TV App, Shares Rise
- App Expansion: Charter announced the launch of its Spectrum TV App on Google TV and other Android TV devices, significantly broadening its streaming service's reach, allowing users to enjoy live TV, Cloud DVR, and On-Demand content, thereby enhancing user experience.
- User Growth Potential: The Spectrum TV App has already become the most-viewed streaming service based on hours-per-household and the highest-rated pay TV streaming app, suggesting that this expansion could further increase its user base and strengthen its competitive position in the market.
- Stock Price Reaction: Following the announcement of the new app, Charter's shares rose 2.6% in the afternoon session, ultimately closing at $221.87, up 3.1% from the previous day, indicating a positive market response to the news.
- Market Volatility: Although Charter's stock has only experienced 7 moves greater than 5% in the past year, this increase suggests market recognition of the new app's significance, even as the overall economic environment remains uncertain, potentially impacting future stock performance.
See More
HPE Secures License for Sisvel Wi-Fi Multimode Patents
- Patent Licensing Agreement: Hewlett Packard Enterprise (HPE) has reached an agreement with Sisvel to become the latest licensee of its Wi-Fi Multimode patent pool, joining companies like Sony, Huawei, Panasonic, Philips, and ZTE, highlighting HPE's significant influence in the global WLAN market.
- Market Position Strengthened: As a leading manufacturer of consumer and enterprise routers, this licensing agreement not only enhances HPE's competitiveness in Wi-Fi 6 and Wi-Fi 7 technologies but also lays a foundation for future technological advancements.
- Amicable Negotiation Outcome: Sisvel's Legal and Licensing Counsel Meagan Leslie noted that HPE's constructive engagement during negotiations led to the agreement, reflecting the professionalism and collaborative spirit of all parties involved in the complex discussions.
- Future Prospects: Sisvel Chief IP Officer Heath Hoglund welcomed HPE's addition and anticipates that more companies will join this patent pool in the near future, further promoting the commercialization and accessibility of Wi-Fi technologies.
See More
Global Sleep Apnea Devices Market Growth Forecast
- Market Size Growth: The global sleep apnea devices market is projected to expand from USD 7.95 billion in 2025 to USD 14.68 billion by 2034, growing at a CAGR of 7.05%, reflecting increased awareness of sleep disorders and technological advancements.
- Expanding Patient Base: Approximately 1 billion individuals globally are affected by sleep apnea, with 936 million suffering from obstructive sleep apnea, and over 30 million in the U.S., indicating significant market demand potential.
- Technological Innovation Drive: Recent advancements have made sleep apnea devices smaller, quieter, and more portable, while the introduction of smart devices enhances treatment effectiveness and patient comfort, propelling market growth.
- Homecare Trend: The increasing preference for home-based healthcare solutions has significantly boosted demand for sleep apnea devices, particularly as insurance coverage expands, making home testing devices like NightOwl more appealing.
See More
Philips Rembra Platform Receives FDA Clearance
- FDA Clearance: Philips' Rembra CT, Rembra RT, and Areta RT systems have received 510(k) clearance from the U.S. FDA, marking a significant advancement in high-throughput imaging and cancer treatment planning, expected to enhance efficiency and quality in healthcare services.
- High-Throughput Imaging Capability: The Rembra CT system supports up to 270 exams per day, designed for emergency, critical care, and interventional settings, enabling clinicians to make timely decisions in critical moments, thus improving the coherence of patient care.
- Precision Treatment Planning: Rembra RT and Areta RT systems feature an 85 cm extended field of view and next-generation 4DCT imaging capabilities, allowing for more accurate tumor targeting while protecting healthy tissue, thereby enhancing the personalization and precision of cancer treatment and reducing variability in the treatment process.
- Integrated Healthcare Workflows: The Rembra platform aims to enhance the efficiency and confidence of healthcare providers by integrating diagnostic and therapeutic solutions, further solidifying Philips' market position in the CT field to meet the growing demand for imaging.
See More
Philips Receives FDA Clearance for First AI-Powered Spectral CT
- FDA Clearance: Philips' Spectral CT Verida system has received FDA 510(k) clearance, becoming the world's first AI-powered spectral CT scanner for clinical use, marking a significant advancement in medical imaging technology.
- Enhanced Imaging Efficiency: The system can reconstruct up to 145 images per second, reducing full-body exam times to under 30 seconds and supporting up to 270 exams per day, significantly improving workflow efficiency in high-volume departments.
- Broad Clinical Applications: The Verida system is cleared for head, whole-body, cardiac, and vascular CT imaging, and is also indicated for oncology treatment planning, providing simultaneous conventional and spectral results to enhance tissue characterization capabilities.
- Personalized Adjustments: The updated computing infrastructure allows clinicians to adjust image de-noising levels based on personal preferences, ensuring customization without compromising spectral output, further enhancing the accuracy of clinical decision-making.
See More
Philips Launches AI-Powered Spectral CT System
- FDA Clearance: Philips' Spectral CT Verida system has received FDA 510(k) clearance, marking the entry of its AI-powered spectral CT innovation into the U.S. market, which is expected to enhance imaging quality and clinical decision-making efficiency.
- Image Reconstruction Capability: The Verida system reconstructs 145 images per second, allowing entire exams to be completed in under 30 seconds, which is twice as fast as before, significantly improving workflow efficiency to meet high patient throughput demands in radiology.
- Broad Clinical Applications: This system is applicable across radiology, interventional radiology, and cardiology, capturing both high- and low-energy data simultaneously, which supports enhanced tissue characterization and material differentiation, thereby improving clinical insights from imaging.
- Market Strategy Expansion: By combining spectral imaging with AI reconstruction, Verida not only enhances image quality but also expands the role of CT across clinical pathways, bolstering Philips' competitive position in the healthcare technology sector.
See More
Charter Launches Spectrum TV App, Shares Rise
- App Expansion: Charter announced the launch of its Spectrum TV App on Google TV and other Android TV devices, significantly broadening its streaming service's reach, allowing users to enjoy live TV, Cloud DVR, and On-Demand content, thereby enhancing user experience.
- User Growth Potential: The Spectrum TV App has already become the most-viewed streaming service based on hours-per-household and the highest-rated pay TV streaming app, suggesting that this expansion could further increase its user base and strengthen its competitive position in the market.
- Stock Price Reaction: Following the announcement of the new app, Charter's shares rose 2.6% in the afternoon session, ultimately closing at $221.87, up 3.1% from the previous day, indicating a positive market response to the news.
- Market Volatility: Although Charter's stock has only experienced 7 moves greater than 5% in the past year, this increase suggests market recognition of the new app's significance, even as the overall economic environment remains uncertain, potentially impacting future stock performance.
See More
HPE Secures License for Sisvel Wi-Fi Multimode Patents
- Patent Licensing Agreement: Hewlett Packard Enterprise (HPE) has reached an agreement with Sisvel to become the latest licensee of its Wi-Fi Multimode patent pool, joining companies like Sony, Huawei, Panasonic, Philips, and ZTE, highlighting HPE's significant influence in the global WLAN market.
- Market Position Strengthened: As a leading manufacturer of consumer and enterprise routers, this licensing agreement not only enhances HPE's competitiveness in Wi-Fi 6 and Wi-Fi 7 technologies but also lays a foundation for future technological advancements.
- Amicable Negotiation Outcome: Sisvel's Legal and Licensing Counsel Meagan Leslie noted that HPE's constructive engagement during negotiations led to the agreement, reflecting the professionalism and collaborative spirit of all parties involved in the complex discussions.
- Future Prospects: Sisvel Chief IP Officer Heath Hoglund welcomed HPE's addition and anticipates that more companies will join this patent pool in the near future, further promoting the commercialization and accessibility of Wi-Fi technologies.
See More
